REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that Susan Berland has been appointed to the newly created position of Executive Vice President and Chief Financial Officer. Ms. Berland brings to Atreca over 20 years’ experience in financial and operational management at both large, public multinational firms and private life science companies. Ms. Berland will report directly to Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder, and her appointment is effective immediately.
“Susan is a seasoned leader who has been a key driver of companies’ success, with expertise across diverse areas of financial management, M&A, financings, treasury, corporate governance, and operations,” said Dr. Serafini. “We are delighted to welcome Susan to our expanding leadership team at Atreca and look forward to her playing a critical role in the Company’s growth as we further advance our platform and programs.”
Prior to joining Atreca, Ms. Berland most recently served as Chief Financial Officer at Mendel Biotechnology, and before this, as CFO at Poniard Pharmaceuticals, where she played a key role in closing several strategic financings. Previously, she was CFO of DNA Sciences. Prior to this, Ms. Berland held senior leadership positions at Monsanto Company as Head of Financial Planning and as Director of Mergers & Acquisitions, in which role she oversaw elements of the transition planning and $27 billion integration between Monsanto and Pharmacia & Upjohn. Previously, Ms. Berland was Senior Manager, Treasury for Holnam Inc. She began her career in corporate finance and strategic planning roles at Ameritech Corporation. As a consultant to the life sciences industry, Ms. Berland has advised companies including Veracyte, Inc., Presidio Pharmaceuticals, Ceres, Inc., and Richmond Chemical Co. Ms. Berland holds MBA and BA degrees from the University of Wisconsin - Milwaukee.
Ms. Berland said, “Atreca is advancing a breakthrough technology - Immune Repertoire Capture™ - with an unparalleled ability to identify antibodies, T cell receptors, and antigens driving productive human immune responses. This technology holds great promise for the development of cancer immunotherapeutics and other innovative treatments, and I am excited to work with Atreca’s leadership team to drive these efforts forward.”
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.